Cargando…

FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis

Disclosure: H. Maldonado Rivera: None. A. Subtain: None. S. Pastori: None. J.A. Gonzalez: None. S.R. Vallepu: None. N. Shahid: None. E. Angueira: None. N. Shaaban: None. A 38-year man with PMH of severe plaque psoriasis presented to the ED with complaints of right leg weakness. Patient denied nausea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Hiram Maldonado, Subtain, Ali, Pastori, Santiago, Gonzalez, Javier A, Vallepu, Shirisha R, Shahid, Novera, Angueira, Eugenio, Shaaban, Noreen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555279/
http://dx.doi.org/10.1210/jendso/bvad114.205
_version_ 1785116618664181760
author Rivera, Hiram Maldonado
Subtain, Ali
Pastori, Santiago
Gonzalez, Javier A
Vallepu, Shirisha R
Shahid, Novera
Angueira, Eugenio
Shaaban, Noreen
author_facet Rivera, Hiram Maldonado
Subtain, Ali
Pastori, Santiago
Gonzalez, Javier A
Vallepu, Shirisha R
Shahid, Novera
Angueira, Eugenio
Shaaban, Noreen
author_sort Rivera, Hiram Maldonado
collection PubMed
description Disclosure: H. Maldonado Rivera: None. A. Subtain: None. S. Pastori: None. J.A. Gonzalez: None. S.R. Vallepu: None. N. Shahid: None. E. Angueira: None. N. Shaaban: None. A 38-year man with PMH of severe plaque psoriasis presented to the ED with complaints of right leg weakness. Patient denied nausea, vomiting, headache, chest pain, shortness of breath, and tremors. His skin psoriasis has been affecting him since childhood but got worse at age 24. The patient has been using clobetasol creams to reduce the itchiness and scaly skin that is formed throughout his body. Patient had morning cortisol level of 2.0 mcg/dL (n >15 mcg/dL). Patient’s cortisol level increased to 13.6 mcg/dL in the first 30 minutes and 17.0 mcg/dL at 60 minutes of corticotropin stimulation test. Based on the result, patient is diagnosed with adrenal insufficiency due to values of cortisol being <18.0mcg/dL. ACTH levels measured at the start were 22.1 pg/mL (n 6-76 pg/mL). This patient’s adrenal insufficiency is potentially multifactorial. The patient may have secondary adrenal insufficiency due to chronic use of clobetasol, a medium-potency topical steroid which has been associated with adrenal insufficiency with prolonged use. This is the most probable diagnosis in the presence of stable blood pressure and in the absence of nausea, vomiting, hyponatremia, hyperkalemia, hypercalcemia, and eosinophilia. However, the patient’s lack of gaining weight and hyperpigmentation seen in the lips and tongue as well as psoriasis, autoimmune skin disease condition may predispose the patient to develop primary adrenal insufficiency. In that case, the patient would need lifelong treatment with PO steroids, especially needing stress dosing if he becomes severely ill. This patient may be developing a primary adrenal insufficiency due to a potential autoimmune adrenalitis. Currently, patient has adequate blood pressure and electrolytes, which suggest he may develop disease later and is currently not in need of fludrocortisone. Patient’s anti-adrenal antibodies, anti-21-hydroxylase antibodies were negative. Patient was started on a medium stress dose of prednisone 20 mg PO in AM and 10 mg in PM. Patient was discharged with prednisone 10 mg PO in AM and 5 mg in PM (this is the equivalent of 40mg of hydrocortisone in AM and 20mg of Hydrocortisone in PM due to moderate illness). Eventually, patient’s prednisone dose was tapered to 5 mg in AM and 2.5mg in PM. Conclusion: This is a very rare case of clobetasol, a medium potency topical steroid used to treat severe plaque psoriasis causing secondary adrenal insufficiency due to negative feedback inhibition of hypothalamus-pituitary-adrenal axis. Reference: Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal Suppression following Low-Dose Topical Clobetasol Propionate. Journal of the Royal Society of Medicine. 1987;80(7):422-424.doi:10.1177/014107688708000709 Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10555279
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105552792023-10-06 FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis Rivera, Hiram Maldonado Subtain, Ali Pastori, Santiago Gonzalez, Javier A Vallepu, Shirisha R Shahid, Novera Angueira, Eugenio Shaaban, Noreen J Endocr Soc Adrenal (Excluding Mineralocorticoids) Disclosure: H. Maldonado Rivera: None. A. Subtain: None. S. Pastori: None. J.A. Gonzalez: None. S.R. Vallepu: None. N. Shahid: None. E. Angueira: None. N. Shaaban: None. A 38-year man with PMH of severe plaque psoriasis presented to the ED with complaints of right leg weakness. Patient denied nausea, vomiting, headache, chest pain, shortness of breath, and tremors. His skin psoriasis has been affecting him since childhood but got worse at age 24. The patient has been using clobetasol creams to reduce the itchiness and scaly skin that is formed throughout his body. Patient had morning cortisol level of 2.0 mcg/dL (n >15 mcg/dL). Patient’s cortisol level increased to 13.6 mcg/dL in the first 30 minutes and 17.0 mcg/dL at 60 minutes of corticotropin stimulation test. Based on the result, patient is diagnosed with adrenal insufficiency due to values of cortisol being <18.0mcg/dL. ACTH levels measured at the start were 22.1 pg/mL (n 6-76 pg/mL). This patient’s adrenal insufficiency is potentially multifactorial. The patient may have secondary adrenal insufficiency due to chronic use of clobetasol, a medium-potency topical steroid which has been associated with adrenal insufficiency with prolonged use. This is the most probable diagnosis in the presence of stable blood pressure and in the absence of nausea, vomiting, hyponatremia, hyperkalemia, hypercalcemia, and eosinophilia. However, the patient’s lack of gaining weight and hyperpigmentation seen in the lips and tongue as well as psoriasis, autoimmune skin disease condition may predispose the patient to develop primary adrenal insufficiency. In that case, the patient would need lifelong treatment with PO steroids, especially needing stress dosing if he becomes severely ill. This patient may be developing a primary adrenal insufficiency due to a potential autoimmune adrenalitis. Currently, patient has adequate blood pressure and electrolytes, which suggest he may develop disease later and is currently not in need of fludrocortisone. Patient’s anti-adrenal antibodies, anti-21-hydroxylase antibodies were negative. Patient was started on a medium stress dose of prednisone 20 mg PO in AM and 10 mg in PM. Patient was discharged with prednisone 10 mg PO in AM and 5 mg in PM (this is the equivalent of 40mg of hydrocortisone in AM and 20mg of Hydrocortisone in PM due to moderate illness). Eventually, patient’s prednisone dose was tapered to 5 mg in AM and 2.5mg in PM. Conclusion: This is a very rare case of clobetasol, a medium potency topical steroid used to treat severe plaque psoriasis causing secondary adrenal insufficiency due to negative feedback inhibition of hypothalamus-pituitary-adrenal axis. Reference: Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal Suppression following Low-Dose Topical Clobetasol Propionate. Journal of the Royal Society of Medicine. 1987;80(7):422-424.doi:10.1177/014107688708000709 Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10555279/ http://dx.doi.org/10.1210/jendso/bvad114.205 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adrenal (Excluding Mineralocorticoids)
Rivera, Hiram Maldonado
Subtain, Ali
Pastori, Santiago
Gonzalez, Javier A
Vallepu, Shirisha R
Shahid, Novera
Angueira, Eugenio
Shaaban, Noreen
FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis
title FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis
title_full FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis
title_fullStr FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis
title_full_unstemmed FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis
title_short FRI210 Rare Clobetasol Induced Adrenal Insufficiency In A Patient With Chronic Psoriasis
title_sort fri210 rare clobetasol induced adrenal insufficiency in a patient with chronic psoriasis
topic Adrenal (Excluding Mineralocorticoids)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555279/
http://dx.doi.org/10.1210/jendso/bvad114.205
work_keys_str_mv AT riverahirammaldonado fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT subtainali fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT pastorisantiago fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT gonzalezjaviera fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT vallepushirishar fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT shahidnovera fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT angueiraeugenio fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis
AT shaabannoreen fri210rareclobetasolinducedadrenalinsufficiencyinapatientwithchronicpsoriasis